Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 1,165,673, a decrease of 9.3% compared to RMB 1,285,031 in 2024[3] - Gross profit for the same period was RMB 760,204, reflecting a decline of 20.3% from RMB 953,508 in 2024[3] - Loss attributable to equity holders of the parent company was RMB 675,460, an increase of 143.6% from RMB 277,234 in 2024[3] - The company reported a pre-tax loss of RMB 766,557, compared to RMB 290,718 in the previous year[4] - Other income and gains for the year ended December 31, 2025, totaled RMB 29,737,000, a decrease of 9.6% from RMB 32,847,000 in 2024[38] - The current income tax expense for the year ended December 31, 2025, was RMB 12,003,000, a decrease of 35.4% from RMB 18,555,000 in 2024[42] - The group did not recommend any dividend payment for the year ended December 31, 2025, consistent with 2024[45] - The company reported a net loss of RMB 743.7 million for 2025, an increase of RMB 465.3 million from a loss of RMB 278.4 million in 2024, primarily due to impairment provisions related to certain R&D projects[122] Assets and Liabilities - Total non-current assets decreased to RMB 4,501,550 from RMB 4,926,924 in 2024[7] - Current assets totaled RMB 2,042,923, down from RMB 2,387,397 in 2024[7] - Total liabilities increased slightly to RMB 3,092,944 from RMB 3,090,268 in 2024[7] - As of December 31, 2025, the net current liabilities amounted to RMB 1,050,021,000, an increase from RMB 702,871,000 in 2024[8] - Total assets minus current liabilities were recorded at RMB 3,451,529,000, down from RMB 4,224,053,000 in 2024[8] - The total non-current liabilities decreased to RMB 515,020,000 from RMB 612,945,000 in the previous year[8] - The company's equity attributable to owners of the parent was RMB 2,759,191,000, a decline from RMB 3,365,520,000 in 2024[8] Research and Development - The company incurred research and development expenses of RMB 191,275, down from RMB 363,126 in 2024[4] - The company operates five validated human vaccine technology platforms and has four wholly-owned vaccine production enterprises[54] - The company has 20 vaccine products in development across 12 disease areas, with 24 clinical approvals and 24 ongoing clinical trials, including 7 innovative vaccines in Class 1[55] - The company is actively advancing the development of its vaccine product pipeline through continuous technological innovation[75] Market and Sales - Vaccine sales accounted for RMB 1,165,662 in 2025, down from RMB 1,261,446 in 2024, representing a decline of 7.6%[35] - Revenue from mainland China was RMB 1,165,298 in 2025, compared to RMB 1,278,217 in 2024, indicating a decrease of 8.8%[32] - Revenue from other countries/regions dropped to RMB 375 in 2025 from RMB 6,814 in 2024, a decline of 94.5%[32] - The company has commercialized eight vaccine products targeting six disease areas, with recombinant hepatitis B vaccine and freeze-dried rabies vaccine being key products in the market[62] Inventory and Receivables - The company's inventory balance as of December 31, 2025, was RMB 347.4 million, a decrease of RMB 115.2 million or 24.9% from RMB 462.6 million as of December 31, 2024, primarily due to improved inventory management and provisions for near-expiry vaccines[125] - Trade receivables rose to RMB 1,241,722,000 in 2025 from RMB 1,173,906,000 in 2024, with a net trade receivable balance of RMB 1,197,595,000 after impairment[48] - The impairment loss for trade receivables decreased to RMB 44,127,000 in 2025 from RMB 51,153,000 in 2024[50] Financial Management - The company has successfully renewed bank loans amounting to RMB 134,620,000 and secured new bank loans of RMB 176,232,000 after December 31, 2025[14] - Cash and cash equivalents decreased to RMB 342,578 from RMB 494,265 in 2024[7] - The company's financing costs for 2025 were RMB 57.8 million, a decrease of RMB 3.0 million or 4.9% from RMB 60.8 million in 2024, primarily due to reduced bank loan balances and interest rates[120] Regulatory and Compliance - The group has adopted the revised International Accounting Standard No. 21 regarding the lack of exchangeability for the first time in the current financial statements[20] - The group plans to apply new and amended International Financial Reporting Standards when they become effective[21] - The company is committed to adhering to Good Manufacturing Practices (GMP) to ensure quality assurance in its production processes[152] Strategic Initiatives - The company is focused on expanding its market presence and exploring new strategies for growth[149] - The company plans to leverage its 20-year sales network and brand reputation to facilitate the market entry of new products, including the serum-free rabies vaccine[106] - The company aims to deepen cooperation with "Belt and Road" countries to address unmet medical needs globally[107] Employee and Corporate Governance - As of December 31, 2025, the company expects to have approximately 1,466 employees, increasing to about 1,535 by December 31, 2024[137] - Total employee benefit expenses, including director remuneration, are projected to be RMB 344.5 million for 2025, down from RMB 356.9 million in 2024[137] - The audit committee, consisting of three independent non-executive directors, has reviewed the financial results for the year ending December 31, 2025[143]
艾美疫苗(06660) - 2025 - 年度业绩